NVL-330

Phase 1Small molecule

NNuvalent Inc.

NVL-330 is one of 6 small molecule programs targeting Locally Advanced Solid Tumor. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Locally Advanced Solid TumorRecruiting

Locally Advanced Solid TumorPhase 1

Recruiting

Competition

Competitive Landscape

7 competitors in Locally Advanced Solid Tumor

#DrugCompanyPhaseTrials

Disitamab Vedotin

Pfizer

Phase 1

1 2

VC004

JJiangsu vcare pharmaceutical technology co., LTD

Phase 3

1 3

ES014

EElpiscience Biopharma, Ltd.

Phase 1

1 4

Jideytro

NNuvalent Inc.

Preclinical

1 5

NVL-330

NNuvalent Inc.

Phase 1

1 6

TST003

SSuzhou Transcenta Therapeutics Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Locally Advanced Solid Tumor

NCT06521554

Clinical

Trials by Indication[1]

Locally Advanced Solid Tumor1 trial

A Phase 1a/1b Study of the Selective Tyrosine Kinase Inhibitor NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)

Recruiting·NNuvalent Inc.·Phase 1·NCT06521554·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NVL-330. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NVL-330 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NVL-330. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nuvalent Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: NNuvalent Inc.

NVL-330

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Locally Advanced Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News